Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | PRF1 | P14222 | 1/20 | 0.36 |
| ▸ | TDP2 | O95551 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | IKBKB | O14920 | 2/20 | 0.34 |
| ▸ | CHUK | O15111 | 2/20 | 0.34 |
| ▸ | PIP4K2A | P48426 | 3/20 | 0.34 |
| ▸ | PIP4K2B | P78356 | 3/20 | 0.34 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.33 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1543810 | 0.76 | CYP3A4 (0.49) | PDPK1CYP3A4PRF1TDP2BRD4 | |
| SCHEMBL2128431 | 0.76 | CYP3A4 (0.49) | PDPK1CYP3A4PRF1TDP2BRD4 | |
| SCHEMBL1542617 | 0.75 | CYP3A4 (0.59) | PDPK1CYP3A4PRF1TDP2BRD4 | |
| SCHEMBL2127703 | 0.75 | CYP3A4 (0.59) | PDPK1CYP3A4PRF1TDP2BRD4 | |
| SCHEMBL2691334 | 0.75 | CYP3A4 (0.50) | PDPK1CYP3A4TDP2BRD4CREBBP | |
| SCHEMBL1542826 | 0.71 | RAB9A (0.45) | CYP3A4 | |
| SCHEMBL2691615 | 0.71 | CYP3A4 (0.48) | PDPK1CYP3A4TDP2BRD4CREBBP | |
| SCHEMBL861517 | 0.70 | CYP3A4 (0.39) | PDPK1CYP3A4TDP2BRD4IKBKB | |
| SCHEMBL861509 | 0.70 | CYP3A4 (0.36) | PDPK1CYP3A4TDP2BRD4IKBKB | |
| SCHEMBL13030260 | 0.67 | CYP3A4 (0.39) | PDPK1CYP3A4BRD4IKBKBCHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168792-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-05-01 | — | — | US | disclosed |
| EP-2403844-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2012-01-11 | — | — | EP | disclosed |
| WO-2010100178-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-10 | — | — | WO | disclosed |
| US-20100226879-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ABBOT SARAH C | 2010-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100226879-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | POLR2A, IFNAR1, RRM2B | PDPK1 4535/4885CYP3A4 778/4885PRF1 2444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.